CH485752A - Process for the preparation of basic substituted heterocycles - Google Patents

Process for the preparation of basic substituted heterocycles

Info

Publication number
CH485752A
CH485752A CH1011567A CH1011567A CH485752A CH 485752 A CH485752 A CH 485752A CH 1011567 A CH1011567 A CH 1011567A CH 1011567 A CH1011567 A CH 1011567A CH 485752 A CH485752 A CH 485752A
Authority
CH
Switzerland
Prior art keywords
sep
formula
acid
preparation
dibenzo
Prior art date
Application number
CH1011567A
Other languages
German (de)
Inventor
Jean Dr Schmutz
Fritz Dr Hunziker
Martin Kuenzle Franz
Original Assignee
Wander Ag Dr A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wander Ag Dr A filed Critical Wander Ag Dr A
Priority to CH1011567A priority Critical patent/CH485752A/en
Priority to CH1909269A priority patent/CH485765A/en
Priority to CH1909469A priority patent/CH485749A/en
Priority to CH1909369A priority patent/CH485748A/en
Priority to CH1909569A priority patent/CH485750A/en
Priority to CH853970A priority patent/CH514612A/en
Priority to CH751571A priority patent/CH517759A/en
Priority to CH854070A priority patent/CH499539A/en
Priority to IL2957168A priority patent/IL29571A/en
Priority to DE19681720007 priority patent/DE1720007A1/en
Priority to AT00210/70A priority patent/AT292722B/en
Priority to GB00561/68A priority patent/GB1216523A/en
Priority to AT00204/70A priority patent/AT292716B/en
Priority to AT00206/70A priority patent/AT292718B/en
Priority to AT00207/70A priority patent/AT292719B/en
Priority to AT215368A priority patent/AT292707B/en
Priority to AT00205/70A priority patent/AT292717B/en
Priority to SE03129/68A priority patent/SE364277B/xx
Priority to NO94668A priority patent/NO123459B/no
Priority to FR143389A priority patent/FR8046M/fr
Priority to BE712114D priority patent/BE712114A/xx
Priority to NL6803570A priority patent/NL6803570A/xx
Priority to US769373A priority patent/US3539573A/en
Publication of CH485752A publication Critical patent/CH485752A/en
Priority to US29279A priority patent/US3683034A/en
Priority to US00060976A priority patent/US3758479A/en
Priority to US00228747A priority patent/US3793325A/en
Priority to US00342399A priority patent/US3852446A/en
Priority to US435430A priority patent/US3908010A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Description

  

  Verfahren zur Herstellung basisch substituierter     Heterocyclen       Die Erfindung betrifft ein Verfahren zur Herstel  lung von     11-basisch    substituierten     Dibenz[b,f]-1,4-oxa-          zepinen,        Dibenzo[b,f]-1,4-thiazepinen    und     Dibenzo[-          b,el-1,4-diazepinen    der Formel:  
EMI0001.0008     
    sowie von     Säure-Additionssalzen    davon. In Formel<B>1</B>  stellt Z ein Sauerstoffatom, ein Schwefelatom oder eine       Iminogruppe    dar.

   R, ist Wasserstoff, niedriges     Alkyl,     <B>c</B>  niedriges     Hydroxyalkyl,    welches     acyllert    sein kann,  oder     Alkoxyalk-vl    mit höchstens<B>5</B>     C-Atomen.     



  Unter  niedrigem      Alkyl        usw.    wird solches mit<B>1</B>  bis<B>3</B>     C-Atomen    verstanden,  Die     oewünschten    Produkte werden erhalten, wenn  man eine     Verbindun2    der Formel:  
EMI0001.0021     
    worin Z die genannte Bedeutung hat und X einen mit  <B>C</B> C  dem Wasserstoff von Aminen     abspaltbaren    Rest dar-    stellt, mit     Piperazin        bzw.    einem     Piperazinderivat    der  Formel:  
EMI0001.0026     
    worin R, die oben angegebene Bedeutung hat, umsetzt.

    Als ein mit dem Wasserstoff von Aminen     abspalt-          barer    Rest, welcher     kovalent    oder gegebenenfalls auch  ionisch an das     Kohlenstoffatom    gebunden sein kann,  kommt vorzugsweise ein Halogenatom, die     Sulfhydril-          gruppe,    eine gegebenenfalls aktivierte     Alkoxy-    oder       Alkylmercaptogruppe.    beispielsweise die     Methoxy-,          Thiomethyl-    oder     p-Nitrobenzylthiogruppe,    oder ein       Tosvlrest    in Betracht.  



       Äusgangsstoffe    der Formel     II    erhält man beispiels  weise durch     Cberführen    von     Lactamen    der Formel:  
EMI0001.0043     
    worin Z die     -enannte    Bedeutung hat, in die     Thiolac-          tame,        aewünschtenfalls    unter     nachfol-ender        Alk-vlie-          rung    der letzteren, oder durch Umsetzen der     Lactame     mit einem     Halogenierungsmittel,

      wie     Phosphoroxychlo-          rid    oder     Phosphorpentachlorid,    vorzugsweise in Gegen  wart katalytischer     Nlen    en von     Dimethylanilin    oder  <B>9</B>       Dimethylformarnid.        Lactame    der Formel IV sind ihrer  seits durch Ringschluss von Verbindungen der For  meln:

      
EMI0002.0001     
    worin Z die     2enannte    Bedeutung hat und R., Wasser  stoff oder niedriges     Alkyl    bedeutet, oder  
EMI0002.0004     
    worin Z die     -enannte        Bedeutun#z    hat und     Hal    für ein       lialo2enatom    steht, erhältlich.  



       Üle        in    der beschriebenen Weise erhaltenen Basen  sind in den     nielsten    Fällen     kristallisierbar,    sonst im  Hochvakuum     unzersetzt    destillierbar, und bilden mit       anor±!anisclien    und     or,-,anischen    Säuren, beispielsweise  Salzsäure,     Brornwasserstoffsäure,    Schwefelsäure, Salpe  tersäure.

   Phosphorsäure.     Essi2säure,        Oxalsäure,          Maleinsäure,    Weinsäure,     Toluolsilfonsäure    u.     dgl.,    in  Wasser     beständiLe    Additionssalze. in welcher Form die  Produkte ebenfalls verwendet werden können.  



  Die in der beschriebenen Weise erhaltenen Basen  und ihre     Säure-Additionssalze    sind neue     Verbindun-          cen.    die als Wirkstoffe in Arzneimitteln Verwendung  finden. Sie üben eine     -,ünsti-,e        Wirkun,-,    auf das     Zen-          tralnervens-#,-stem    aus und fallen als     Neuroleptika.     Sedativa und insbesondere als     Antiemetika    in Betracht.  



  Die     antiemetische    Wirkung äussert sich     pharmako-          lo21sch    bei Hunden und Ratten in einem     Anta2onismus          ce2enüber    der Wirkung von     Apomorphin.    Als     beson-          C   <B>- C</B>       ders    wirksam hat sich das gemäss Beispiel<B>1</B> erhaltene       Z-'\,fethvlsulfonyl-1        1-(4-rnethyl-   <B>1</B>     -piperazinyl)-dibenz-          [b,f]-1,

  #-oxa-zepin        e#rwiesen.     
EMI0002.0046     
  
    <I>Tabelle</I>
<tb>  Beispiel
<tb>  <B>Z <SEP> iz,</B> <SEP> physikalische <SEP> Konstanten
<tb>  <B><U>1)</U></B> <SEP> H <SEP> Base: <SEP> <B>Smp. <SEP> 189-191 <SEP> ## <SEP> C</B>
<tb>  <B>0</B> <SEP> (aus <SEP> Ac/Ae/Pe)
<tb>  <B>3 <SEP> -CH,</B> <SEP> Base: <SEP> Smp. <SEP> <B>219-223' <SEP> C</B>
<tb>  <B>s</B> <SEP> (aus <SEP> Ac/Pe)
<tb>  H <SEP> Base: <SEP> Smp. <SEP> <B>180-1833 <SEP> C</B>
<tb>  <B>S</B> <SEP> (aus <SEP> <B>ChTe)</B>
<tb>  <B><I>5</I> <SEP> -CH,</B> <SEP> Dihydrobrorrtid: <SEP> Smp. <SEP> <B>225-230' <SEP> C</B>
<tb>  <B>NH</B> <SEP> (Zers.; <SEP> aus <SEP> Me,;Essigf--ster)
<tb>  <B>6</B> <SEP> H <SEP> Dihydrobron-#d:

   <SEP> Smp. <SEP> <B>233-248- <SEP> C</B>
<tb>  <B>NH</B> <SEP> (aus <SEP> MelEssiaester)
<tb>  <B>C</B>
<tb>  <B>7 <SEP> -CH.,-CH:,</B> <SEP> Base: <SEP> Smp. <SEP> <B>190-1911 <SEP> C</B>
<tb>  <B>0</B> <SEP> (aus <SEP> Ac!Pe)
<tb>  <B>8 <SEP> -CH.#-CH.,OH</B> <SEP> Base: <SEP> Smp. <SEP> <B>175-177- <SEP> C</B>
<tb>  <B>0</B> <SEP> (aus <SEP> Ac/Pe)
<tb>  <B>9 <SEP> -CH.,-CH.,OCH:,</B> <SEP> Base:

   <SEP> Smp. <SEP> 146-149## <SEP> <B>C</B>
<tb>  <B>0</B> <SEP> (aus <SEP> Ac/Pe)       <I>Beispiel<B>1</B></I>  <B>5 g</B>     2-Methytsulfonyt-1,1        1-dihydro#-1        1--oxo-dibenz          [b,2-1,4-o#xazepin        (Smp.    242-244--<B>Q</B> werden     n-ü     <B>1,8</B> ml     N,N-Dimethylmüin    und<B>50</B>     ral        Phosphorox#          chlorid    während<B>5</B> Stunden unter Rückfluss erhitzt  worauf das     Reaktionsgernisch    im Vakuum zur     Trockn,     eingeengt wird.

   Der Rückstand wird mit     Xylol    versetz  und nochmals eingedampft. Hierauf wird der Rück  stand in     Xylol    gelöst und auf Eis gegossen,     worau     man dreimal mit     Xyloi    ausschüttelt. Die     Xylollösun#     wird mit verdünnter Salzsäure, Wasser und wässrige       Natriumchloridlösung    gewaschen, mit Natriumsulfat     ge     trocknet. mit Aktivkohle behandelt und durch     weni,     Aluminiumoxid filtriert.

   Das Filtrat wird     ein2een(#t        un(     dann mit 12     m]        N-,Ivieth#rlpiperazin    während<B>6</B> Stunde:  unter     Rückfluss    erhitzt.

   Das     ReaktionsLemisch        wirc     mit Wasser und konzentrierter     Natronlauee    versetz  und zweimal mit Äther     ausuleschütteit.    Die     Ä#herauszü(-l#     werden mehrmals mit Wasser     Pewaschen    und dann     Ml'     verdünnter Salzsäure     ausgescl:Ittelt.    Die sauren Aus  züge werden alkalisch     -,estellt    und zweimal mit     Äthe:     extrahiert.

   Die Ätherphasen werden mit Wasser     un(          wässri-er        Natriuinchloridlösun2        -ewaschen,    mit     Natri-          umsulfat        2etrock-liet,        mit    Aktivkohle behandelt     un(     durch wenig     Aluminiumoxid    filtriert. Das Filtrat     wirc     stark eingedampft und mit     Petroläther    versetzt.

   Die ab  geschiedenen Kristalle     Nverden    in Aceton     Oelöst        und-          c     nach starkem Eindampfen der Lösung. auf Zusatz vor       Äther/Petroläther    umkristallisiert. Man erhält<B>5.8</B><U>L</U>       2-Methylsulfonyl-1   <B>1</B>     -(4-methyl-1        -piperazinyl)-dibenz-          [b,f]-1,4-oxazepin    in Form von schwach gelblichen  Nadeln vom Schmelzpunkt     178-179'   <B>C.</B>  



  Bei analogem Vorgehen     %vie    im     vorer%\ähriten    Bei  spiel erhält man weiterhin die in der     nachfoleenden     Tabelle erwähnten Produkte entsprechend Formel<B>1. In</B>  der Tabelle haben R, und Z die früher genannte Be  deutung. In der Kolonne rechts     bedeutJ        Ac    Aceton.       Ae    Äther,     Ch    Chloroform.     Ni1c    Methanol und     Pe        Petrol-          äther.  



  Process for the Production of Basically Substituted Heterocycles The invention relates to a process for the production of 11-base substituted dibenz [b, f] -1,4-oxazepines, dibenzo [b, f] -1,4-thiazepines and dibenzo [- b, el-1,4-diazepines of the formula:
EMI0001.0008
    as well as acid addition salts thereof. In formula <B> 1 </B>, Z represents an oxygen atom, a sulfur atom or an imino group.

   R 1 is hydrogen, lower alkyl, lower hydroxyalkyl, which can be acyl-tertiary, or alkoxyalkylene with a maximum of 5 carbon atoms.



  Lower alkyl, etc. is understood as meaning those with <B> 1 </B> to <B> 3 </B> carbon atoms. The desired products are obtained when a compound of the formula:
EMI0001.0021
    where Z has the meaning mentioned and X is a radical which can be split off from amines with the hydrogen with C, with piperazine or a piperazine derivative of the formula:
EMI0001.0026
    wherein R, has the meaning given above, reacts.

    A halogen atom, the sulfhydryl group, an optionally activated alkoxy or alkyl mercapto group, can be used as a radical which can be split off from amines with the hydrogen and which can be covalently or optionally also ionically bonded to the carbon atom. for example the methoxy, thiomethyl or p-nitrobenzylthio group, or a tosyl radical.



       Starting materials of the formula II are obtained, for example, by converting lactams of the formula:
EMI0001.0043
    where Z has the meaning mentioned, into the thiolactams, if desired with subsequent alkification of the latter, or by reacting the lactams with a halogenating agent,

      such as phosphorus oxychloride or phosphorus pentachloride, preferably in the presence of catalytic compounds of dimethyl aniline or 9 dimethyl formamide. Lactams of the formula IV are in turn formed by ring closure of compounds of the formulas:

      
EMI0002.0001
    wherein Z has the meaning mentioned and R., hydrogen or lower alkyl is, or
EMI0002.0004
    in which Z has the meaning mentioned and Hal stands for a lialo2enatom.



       Oils obtained in the manner described are in most cases crystallizable, otherwise they can be distilled without decomposition in a high vacuum, and form with inorganic, anic and or, anic acids, for example hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid.

   Phosphoric acid. Acetic acid, oxalic acid, maleic acid, tartaric acid, toluenesilfonic acid and the like Like., addition salts which are stable in water. in which form the products can also be used.



  The bases obtained in the manner described and their acid addition salts are new compounds. which are used as active ingredients in pharmaceuticals. They exert a -, ünsti-, e effect -, on the central nerve - #, - system and fall as neuroleptics. Sedatives and especially as antiemetics into consideration.



  The antiemetic effect manifests itself pharmacologically in dogs and rats in an antagonism over the effect of apomorphine. The Z - '\, fethvlsulfonyl-1 1- (4-methyl- <B> 1 </B>) obtained according to Example <B> 1 </B> has proven to be particularly effective. B> -piperazinyl) -dibenz- [b, f] -1,

  # -oxa-zepin e # proven.
EMI0002.0046
  
    <I> table </I>
<tb> example
<tb> <B> Z <SEP> iz, </B> <SEP> physical <SEP> constants
<tb> <B><U>1)</U> </B> <SEP> H <SEP> Base: <SEP> <B> Smp. <SEP> 189-191 <SEP> ## <SEP> C </B>
<tb> <B> 0 </B> <SEP> (from <SEP> Ac / Ae / Pe)
<tb> <B> 3 <SEP> -CH, </B> <SEP> Base: <SEP> Smp. <SEP> <B> 219-223 '<SEP> C </B>
<tb> <B> s </B> <SEP> (from <SEP> Ac / Pe)
<tb> H <SEP> Base: <SEP> Smp. <SEP> <B> 180-1833 <SEP> C </B>
<tb> <B> S </B> <SEP> (from <SEP> <B> ChTe) </B>
<tb> <B> <I> 5 </I> <SEP> -CH, </B> <SEP> Dihydrobrorrtid: <SEP> Smp. <SEP> <B> 225-230 '<SEP> C </ B>
<tb> <B> NH </B> <SEP> (dec .; <SEP> from <SEP> Me,; vinegar window)
<tb> <B> 6 </B> <SEP> H <SEP> Dihydrobron- # d:

   <SEP> Smp. <SEP> <B> 233-248- <SEP> C </B>
<tb> <B> NH </B> <SEP> (from <SEP> MelEssiaester)
<tb> <B> C </B>
<tb> <B> 7 <SEP> -CH., - CH :, </B> <SEP> Base: <SEP> Smp. <SEP> <B> 190-1911 <SEP> C </B>
<tb> <B> 0 </B> <SEP> (from <SEP> Ac! Pe)
<tb> <B> 8 <SEP> -CH. # - CH., OH </B> <SEP> Base: <SEP> Smp. <SEP> <B> 175-177- <SEP> C </ B >
<tb> <B> 0 </B> <SEP> (from <SEP> Ac / Pe)
<tb> <B> 9 <SEP> -CH., - CH., OCH :, </B> <SEP> Base:

   <SEP> Smp. <SEP> 146-149 ## <SEP> <B> C </B>
<tb> <B> 0 </B> <SEP> (from <SEP> Ac / Pe) <I> Example<B>1</B> </I> <B> 5 g </B> 2- Methytsulfonyt-1,1 1-dihydro # -1 1 - oxo-dibenz [b, 2-1,4-o # xazepine (mp. 242-244-- <B> Q </B> are n-ü < B> 1.8 ml of N, N-dimethylmuine and 50 ral Phosphorox chloride heated under reflux for 5 hours, whereupon the reaction mixture was concentrated to dryness in vacuo becomes.

   The residue is mixed with xylene and evaporated again. The residue is then dissolved in xylene and poured onto ice, whereupon it is extracted three times with xyloi. The xylene solution is washed with dilute hydrochloric acid, water and aqueous sodium chloride solution and dried with sodium sulfate. treated with activated charcoal and filtered through little aluminum oxide.

   The filtrate is heated under reflux for <B> 6 </B> hours (then with 12 m] N-, Ivieth # rlpiperazine.

   The reaction mixture is mixed with water and concentrated caustic soda and poured out twice with ether. The extracts are washed several times with water and then extracted with ml of dilute hydrochloric acid. The acid extracts are made alkaline, and extracted twice with ethers.

   The ether phases are washed with water and aqueous sodium chloride solution, dried with sodium sulfate, treated with activated charcoal and filtered through a little aluminum oxide. The filtrate is strongly evaporated and petroleum ether is added.

   The separated crystals are dissolved in acetone oil and after vigorous evaporation of the solution. recrystallized on addition from ether / petroleum ether. This gives <B> 5.8 </B> <U> L </U> 2-methylsulfonyl-1 <B> 1 </B> - (4-methyl-1 -piperazinyl) -dibenz- [b, f] - 1,4-oxazepine in the form of pale yellowish needles with a melting point of 178-179 '<B> C. </B>



  If you proceed in the same way as in the previous example, you still get the products mentioned in the following table according to formula <B> 1. In the table, R and Z have the meanings given earlier. In the column on the right, acetone means acetone. Ae ether, Ch chloroform. Ni1c methanol and Pe petroleum ether.

 

Claims (1)

<B>PATENTANSPRUCH</B> Verfahren zur Herstellung 11-basisch substituierter C Dibenz[b,f1-1,4-oxazepine, Dibenzo[b,f]-1,4-thiazepine und Dibenzo[b,ej-1,4-diazepine der Formel: <B> PATENT CLAIM </B> Process for the preparation of 11-basic substituted C dibenz [b, f1-1,4-oxazepines, dibenzo [b, f] -1,4-thiazepines and dibenzo [b, ej-1,4 -diazepines of the formula: EMI0003.0005 worin Z ein Sauerstoffatom oder ein Schwefelatom oder eine Iminogruppe darstellt, R, Wasserstoff, nied riges Alkyl, nieäriges Hydroxyalkyl, welches acyliert sein kann, oder Alkoxyalkyl mit höchstens<B>5</B> C-Ato- men bedeutet, sowie von Säure-Additionssalzen davon; dadurch gekennzeichnet, dass man eine Verbindung der Formel: EMI0003.0005 where Z represents an oxygen atom or a sulfur atom or an imino group, R represents hydrogen, lower alkyl, lower hydroxyalkyl, which can be acylated, or alkoxyalkyl with at most 5 carbon atoms, and acid -Addition salts thereof; characterized in that a compound of the formula: EMI0003.0015 worin Z die genannte Bedeutung hat und X einen mit dem Wasserstoff von Aminen abspaltbaren Rest dar stellt, mit Piperazin bzw. einem Piperazinderivat der Formel: EMI0003.0020 worin R, die oben angegebene Bedeutung hat, urnsetzt, <B><I>b</I></B> worauf man die erhaltenen Reaktionsprodukte als freie Base oder in Form ihrer Säure-Additionssalze mit ae- C eigneten anorganischen oder organischen Säuren iso liert. EMI0003.0015 wherein Z has the meaning mentioned and X represents a radical which can be split off from amines with the hydrogen, with piperazine or a piperazine derivative of the formula: EMI0003.0020 in which R, which has the meaning given above, reacts, whereupon the reaction products obtained are used as a free base or in the form of their acid addition salts with ae-C suitable inorganic or organic acids isolated. <I>Anmerkung des</I> Eidg. <I>Amtes</I> für <I>geistiges Eigentum:</I> Sollten Teile der Beschreibung mit der im Patentanspruch gegebenen Definition der Erfindung nicht in Einklang stehen, so sei daran erinnert, dass gemäss Art.<B>51</B> des Patentgesetzes der Patentanspruch für den sachlichen Geltungsbereich des Patentes massgebend ist. <I> Note from the </I> Federal <I> Office </I> for <I> intellectual property: </I> If parts of the description are inconsistent with the definition of the invention given in the claim, so be aware reminds that according to Art. <B> 51 </B> of the Patent Act, the patent claim is authoritative for the material scope of the patent.
CH1011567A 1963-09-27 1967-07-14 Process for the preparation of basic substituted heterocycles CH485752A (en)

Priority Applications (28)

Application Number Priority Date Filing Date Title
CH1011567A CH485752A (en) 1967-07-14 1967-07-14 Process for the preparation of basic substituted heterocycles
CH1909269A CH485765A (en) 1967-07-14 1967-07-14 Process for the preparation of basic substituted heterocycles
CH1909469A CH485749A (en) 1967-07-14 1967-07-14 Process for the preparation of basic substituted heterocycles
CH1909369A CH485748A (en) 1967-07-14 1967-07-14 Process for the preparation of basic substituted heterocycles
CH1909569A CH485750A (en) 1967-07-14 1967-07-14 Process for the preparation of basic substituted heterocycles
CH853970A CH514612A (en) 1967-03-13 1968-02-14 Process for the preparation of 11-basic substituted dibenz (b, f) -1,4-oxazepines and dibenzo (b, e) -1,4-diazepines
CH751571A CH517759A (en) 1967-03-13 1968-02-14 Process for the preparation of 11-basic substituted dibenz (b, f) -1,4-oxazepines and dibenzo (b, e) -1,4-diazepines
CH854070A CH499539A (en) 1967-03-13 1968-02-14 Cns-active 2-aminosulphonyl-11-piperazinyl- - dibenz-1,4-oxo (or thi or-di) azepines prodn
IL2957168A IL29571A (en) 1967-03-13 1968-03-04 11-substituted dibenzo(b,f)-1,4-oxazepines,dibenzo(b,f)-1,4-thiazepines and dibenzo(b,e)-1,4-diazepines and their preparation
DE19681720007 DE1720007A1 (en) 1967-03-13 1968-03-04 Basically substituted heterocycles
AT00206/70A AT292718B (en) 1967-03-13 1968-03-05 PROCESS FOR THE PRODUCTION OF NEW 11-BASIC SUBSTITUTED DIBENZ<B,F>-1,4-OXAZEPINE, DIBENZO<B,F>-1,4-THIAZEPINE AND DIBENZO<B,E>-1,4-DIAZEPINE AND ACID- ADDITIONAL SALTS THEREOF
GB00561/68A GB1216523A (en) 1967-03-13 1968-03-05 Basically substituted dibenzoxazepines, dibenzothiazepines and dibenzodiazepines
AT00204/70A AT292716B (en) 1967-03-13 1968-03-05 PROCESS FOR THE PRODUCTION OF NEW 11-BASIC SUBSTITUTED DIBENZ<B,F>-1,4-OXAZEPINE, DIBENZO<B,F>-1,4-THIAZEPINE AND DIBENZO<B,E>-1,4-DIAZEPINE AND ACID- ADDITIONAL SALTS THEREOF
AT00210/70A AT292722B (en) 1967-07-14 1968-03-05 PROCESS FOR THE PRODUCTION OF NEW 11-BASIC SUBSTITUTED DIBENZ<B,F>-1,4-OXAZEPINE, DIBENZO<B,F>-1,4-THIAZEPINE AND DIBENZO<B,E>-1,4-DIAZEPINE AND ACID- ADDITIONAL SALTS THEREOF
AT00207/70A AT292719B (en) 1967-07-14 1968-03-05 PROCESS FOR THE PRODUCTION OF NEW 11-BASIC SUBSTITUTED DIBENZ<B,F>-1,4-OXAZEPINE, DIBENZO<B,F>-1,4-THIAZEPINE AND DIBENZO<B,E>-1,4-DIAZEPINE AND ACID- ADDITIONAL SALTS THEREOF
AT215368A AT292707B (en) 1967-03-13 1968-03-05 Process for the production of new 11-basic substituted dibenz [b, f] -1,4-oxazepine, dibenzo [b, f] -1,4-thiazepine and dibenzo [b, e] -1,4-diazepine, as well as acid -Addition salts thereof
AT00205/70A AT292717B (en) 1967-03-13 1968-03-05 PROCESS FOR THE PRODUCTION OF NEW 11-BASIC SUBSTITUTED DIBENZ<B,F>-1,4-OXAZEPINE, DIBENZO<B,F>-1,4-THIAZEPINE AND DIBENZO<B,E>-1,4-DIAZEPINE AND ACID- ADDITIONAL SALTS THEREOF
SE03129/68A SE364277B (en) 1967-03-13 1968-03-08
FR143389A FR8046M (en) 1967-03-13 1968-03-12
NO94668A NO123459B (en) 1967-03-13 1968-03-12
BE712114D BE712114A (en) 1967-03-13 1968-03-13
NL6803570A NL6803570A (en) 1967-03-13 1968-03-13
US769373A US3539573A (en) 1967-03-22 1968-10-21 11-basic substituted dibenzodiazepines and dibenzothiazepines
US29279A US3683034A (en) 1963-09-27 1970-04-16 Process for the preparation of substituted hydroquinones
US00060976A US3758479A (en) 1967-03-22 1970-07-06 Nitro and sulphamoyl substituted dibenzodiazepines
US00228747A US3793325A (en) 1967-03-22 1972-02-23 11-basically substituted dibenz(b,f)(1,4)thiazepine and dibenz(b,e)(1,4)diazepines
US00342399A US3852446A (en) 1967-03-13 1973-03-19 Organic compounds in treatment of psychotic disturbances
US435430A US3908010A (en) 1967-03-22 1974-01-22 Basically substituted heterocycles as anti-emetics

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH1011567A CH485752A (en) 1967-07-14 1967-07-14 Process for the preparation of basic substituted heterocycles

Publications (1)

Publication Number Publication Date
CH485752A true CH485752A (en) 1970-02-15

Family

ID=4359519

Family Applications (5)

Application Number Title Priority Date Filing Date
CH1909469A CH485749A (en) 1967-07-14 1967-07-14 Process for the preparation of basic substituted heterocycles
CH1909569A CH485750A (en) 1967-07-14 1967-07-14 Process for the preparation of basic substituted heterocycles
CH1909269A CH485765A (en) 1967-07-14 1967-07-14 Process for the preparation of basic substituted heterocycles
CH1909369A CH485748A (en) 1967-07-14 1967-07-14 Process for the preparation of basic substituted heterocycles
CH1011567A CH485752A (en) 1963-09-27 1967-07-14 Process for the preparation of basic substituted heterocycles

Family Applications Before (4)

Application Number Title Priority Date Filing Date
CH1909469A CH485749A (en) 1967-07-14 1967-07-14 Process for the preparation of basic substituted heterocycles
CH1909569A CH485750A (en) 1967-07-14 1967-07-14 Process for the preparation of basic substituted heterocycles
CH1909269A CH485765A (en) 1967-07-14 1967-07-14 Process for the preparation of basic substituted heterocycles
CH1909369A CH485748A (en) 1967-07-14 1967-07-14 Process for the preparation of basic substituted heterocycles

Country Status (2)

Country Link
AT (2) AT292719B (en)
CH (5) CH485749A (en)

Also Published As

Publication number Publication date
CH485750A (en) 1970-02-15
CH485748A (en) 1970-02-15
AT292722B (en) 1971-08-15
AT292719B (en) 1971-08-15
CH485765A (en) 1970-02-15
CH485749A (en) 1970-02-15

Similar Documents

Publication Publication Date Title
DE1445845A1 (en) New benzomorphans and methods of making them
DE1695929C3 (en) 1 ^ -Dihydro-1-hydroxy ^ -imino ^ -amino-6-methylpyrimidines and a process for their preparation
DE2241012A1 (en) NEW 3,1-BENZOXAZIN-4-ON DERIVATIVES AND METHOD FOR MANUFACTURING THE SAME
CH485752A (en) Process for the preparation of basic substituted heterocycles
DE1470416A1 (en) Process for the preparation of II-basic substituted 5 H-dibenzo [b, e], [1,4] diazepines
DE1470367A1 (en) Process for the preparation of 5,6-dihydro-6-oxopyrido [2,3-b] [1,4] benzoxazepines substituted in the 5-position
DE1470427C3 (en) Substituted 6-piperazino-morphanthridines
DE1097995B (en) Process for the preparation of phenthiazine derivatives
DE2352107A1 (en) NEW CHEMICAL COMPOUNDS, THEIR PRODUCTION METHODS AND APPLICATIONS OF THESE COMPOUNDS, IN PARTICULAR TO THE SYNTHESIS 2,4-DIAMINO- (3 &#39;, 4&#39;, 5&#39;-TRIMETHOXY-) 1-BENZYL-PYRIMIDINE
DE1795053A1 (en) Process for the preparation of compounds of the benzodiazepine series
AT308754B (en) Process for the preparation of benzodiazepine derivatives and acid addition salts thereof
AT292717B (en) PROCESS FOR THE PRODUCTION OF NEW 11-BASIC SUBSTITUTED DIBENZ&lt;B,F&gt;-1,4-OXAZEPINE, DIBENZO&lt;B,F&gt;-1,4-THIAZEPINE AND DIBENZO&lt;B,E&gt;-1,4-DIAZEPINE AND ACID- ADDITIONAL SALTS THEREOF
DE2012943A1 (en) Novel triazole derivatives and processes for making the same
DE1300954B (en) Process for the production of dibenzothiepin and oxepines
CH495372A (en) Substd. dibenzo(b,f) 1,4 oxazepine and thiazepine (4 oxides) - as neuroleptics
DE1445858C3 (en) 7-cyano-5-phenyl-1,2-dihydro-3H-1,4benzodiazepin-2-one derivatives
AT269371B (en) Process for the production of new N-substituted normorphines
AT269372B (en) Process for the production of new N-substituted benzomorphans
AT211823B (en) Process for the preparation of new aryloxyacetic acid amides
DE1470009C (en) 3.5 dihydro 5 phenyl 4.1 benzoxaze pin 2 ones
DE1545805B2 (en) Process for the preparation of benzothiazine derivatives
AT225193B (en) Process for the preparation of new 2,4-diamino-pyrido- (2,3-d) -pyrimidines
AT337173B (en) PROCESS FOR THE PRODUCTION OF NEW ISOINDOLINE DERIVATIVES AND THEIR SALT
AT203013B (en) Process for the preparation of new N-aminoalkyl derivatives of azepines
AT260935B (en) Process for the preparation of new 5,6-dihydro-5-oxo-11H-pyrido [2,3-b] [1,5] benzodiazepines

Legal Events

Date Code Title Description
PL Patent ceased